Which has preferable valuation and earnings, ORGS or BPTSY?

Biophytis has lower revenue, but higher earnings than Orgenesis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Orgenesis $662K 2.73 -$55.36M -$11.51 N/A Biophytis N/A N/A -$18.43M N/A N/A

Is ORGS or BPTSY more profitable?

Biophytis has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Company Net Margins Return on Equity Return on Assets Orgenesis -3,827.81% N/A -130.18% Biophytis N/A N/A N/A

Which has better earnings and valuation, BPTSY or ATXI?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biophytis N/A N/A -$18.43M N/A N/A Avenue Therapeutics N/A N/A -$10.38M -$0.85 N/A

Is BPTSY or ATXI more profitable?

Biophytis' return on equity of 0.00% beat Avenue Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Biophytis N/A N/A N/A Avenue Therapeutics N/A -471.57% -296.50%

Do analysts rate BPTSY or JAGX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biophytis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Jaguar Animal Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, BPTSY or JAGX?

Biophytis has higher earnings, but lower revenue than Jaguar Animal Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biophytis N/A N/A -$18.43M N/A N/A Jaguar Animal Health $27.79M 0.06 -$53.43M -$248.88 N/A

Is BPTSY or JAGX more profitable?

Biophytis has a net margin of 0.00% compared to Jaguar Animal Health's net margin of -187.88%. Company Net Margins Return on Equity Return on Assets Biophytis N/A N/A N/A Jaguar Animal Health -187.88% N/A -131.45%

Do analysts prefer ITRM or BPTSY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Biophytis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, ITRM or BPTSY?

Biophytis has lower revenue, but higher earnings than Iterum Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Iterum Therapeutics $390K 4.10 -$24.77M -$0.75 N/A Biophytis N/A N/A -$18.43M N/A N/A

Is ITRM or BPTSY more profitable?

Company Net Margins Return on Equity Return on Assets Iterum Therapeutics N/A N/A -65.54% Biophytis N/A N/A N/A

Do analysts rate CANF or BPTSY?

Can-Fite BioPharma currently has a consensus price target of $44.00, indicating a potential upside of 1,788.41%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Can-Fite BioPharma is more favorable than Biophytis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Biophytis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, CANF or BPTSY?

Can-Fite BioPharma has higher revenue and earnings than Biophytis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Can-Fite BioPharma $405K 3.77 -$7.63M -$22.80 N/A Biophytis N/A N/A -$18.43M N/A N/A

Is CANF or BPTSY more profitable?

Company Net Margins Return on Equity Return on Assets Can-Fite BioPharma N/A N/A N/A Biophytis N/A N/A N/A

Biophytis (BPTSY) Competitors

$0.25 0.00 (0.00%)

As of 09/10/2026

Compare

BPTSY vs. ORGS, ATXI, JAGX, ITRM, and CANF

Should you buy Biophytis stock or one of its competitors? Biophytis's main competitors and comparable companies include Orgenesis (ORGS), Avenue Therapeutics (ATXI), Jaguar Animal Health (JAGX), Iterum Therapeutics (ITRM), and Can-Fite BioPharma (CANF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Biophytis compare to Orgenesis?

Orgenesis (NASDAQ:ORGS) and Biophytis (NASDAQ:BPTSY) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

Biophytis has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
Biophytis	N/A	N/A	N/A

22.6% of Orgenesis shares are held by institutional investors. Comparatively, 0.1% of Biophytis shares are held by institutional investors. 1.9% of Orgenesis shares are held by company insiders. Comparatively, 3.7% of Biophytis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Orgenesis has a beta of 3.16, meaning that its share price is 216% more volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, meaning that its share price is 146% more volatile than the broader market.

Biophytis has lower revenue, but higher earnings than Orgenesis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	2.73	-$55.36M	-$11.51	N/A
Biophytis	N/A	N/A	-$18.43M	N/A	N/A

In the previous week, Orgenesis' average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.

Company	Overall Sentiment
Orgenesis	Neutral
Biophytis	Neutral

Summary

Biophytis beats Orgenesis on 4 of the 7 factors compared between the two stocks.

How does Biophytis compare to Avenue Therapeutics?

Biophytis (NASDAQ:BPTSY) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

Biophytis has a beta of 2.46, suggesting that its stock price is 146% more volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.18, suggesting that its stock price is 118% less volatile than the broader market.

Biophytis' return on equity of 0.00% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biophytis	N/A	N/A	N/A
Avenue Therapeutics	N/A	-471.57%	-296.50%

0.1% of Biophytis shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 3.7% of Biophytis shares are owned by insiders. Comparatively, 8.6% of Avenue Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biophytis	N/A	N/A	-$18.43M	N/A	N/A
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.85	N/A

In the previous week, Biophytis' average media sentiment score of 0.00 equaled Avenue Therapeutics'average media sentiment score.

Company	Overall Sentiment
Biophytis	Neutral
Avenue Therapeutics	Neutral

Summary

Biophytis and Avenue Therapeutics tied by winning 3 of the 6 factors compared between the two stocks.

How does Biophytis compare to Jaguar Animal Health?

Biophytis (NASDAQ:BPTSY) and Jaguar Animal Health (NASDAQ:JAGX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

In the previous week, Jaguar Animal Health had 3 more articles in the media than Biophytis. MarketBeat recorded 3 mentions for Jaguar Animal Health and 0 mentions for Biophytis. Jaguar Animal Health's average media sentiment score of 0.32 beat Biophytis' score of 0.00 indicating that Jaguar Animal Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Biophytis	Neutral
Jaguar Animal Health	Neutral

0.1% of Biophytis shares are owned by institutional investors. Comparatively, 12.0% of Jaguar Animal Health shares are owned by institutional investors. 3.7% of Biophytis shares are owned by company insiders. Comparatively, 0.2% of Jaguar Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Biophytis has higher earnings, but lower revenue than Jaguar Animal Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biophytis	N/A	N/A	-$18.43M	N/A	N/A
Jaguar Animal Health	$27.79M	0.06	-$53.43M	-$248.88	N/A

Biophytis has a beta of 2.46, suggesting that its stock price is 146% more volatile than the broader market. Comparatively, Jaguar Animal Health has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biophytis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Jaguar Animal Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biophytis has a net margin of 0.00% compared to Jaguar Animal Health's net margin of -187.88%.

Company	Net Margins	Return on Equity	Return on Assets
Biophytis	N/A	N/A	N/A
Jaguar Animal Health	-187.88%	N/A	-131.45%

Summary

Biophytis and Jaguar Animal Health tied by winning 5 of the 10 factors compared between the two stocks.

How does Biophytis compare to Iterum Therapeutics?

Iterum Therapeutics (NASDAQ:ITRM) and Biophytis (NASDAQ:BPTSY) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Iterum Therapeutics has a beta of 2.96, meaning that its stock price is 196% more volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, meaning that its stock price is 146% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Biophytis	N/A	N/A	N/A

In the previous week, Iterum Therapeutics' average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.

Company	Overall Sentiment
Iterum Therapeutics	Neutral
Biophytis	Neutral

Biophytis has lower revenue, but higher earnings than Iterum Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
Biophytis	N/A	N/A	-$18.43M	N/A	N/A

9.2% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 0.1% of Biophytis shares are held by institutional investors. 2.0% of Iterum Therapeutics shares are held by insiders. Comparatively, 3.7% of Biophytis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Biophytis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Iterum Therapeutics beats Biophytis on 4 of the 7 factors compared between the two stocks.

How does Biophytis compare to Can-Fite BioPharma?

Can-Fite BioPharma (NYSE:CANF) and Biophytis (NASDAQ:BPTSY) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Can-Fite BioPharma has higher revenue and earnings than Biophytis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Can-Fite BioPharma	$405K	3.77	-$7.63M	-$22.80	N/A
Biophytis	N/A	N/A	-$18.43M	N/A	N/A

Can-Fite BioPharma currently has a consensus price target of $44.00, indicating a potential upside of 1,788.41%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Can-Fite BioPharma is more favorable than Biophytis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Biophytis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

21.0% of Can-Fite BioPharma shares are held by institutional investors. Comparatively, 0.1% of Biophytis shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by company insiders. Comparatively, 3.7% of Biophytis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Can-Fite BioPharma has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, indicating that its stock price is 146% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
Biophytis	N/A	N/A	N/A

In the previous week, Can-Fite BioPharma had 4 more articles in the media than Biophytis. MarketBeat recorded 4 mentions for Can-Fite BioPharma and 0 mentions for Biophytis. Biophytis' average media sentiment score of 0.00 beat Can-Fite BioPharma's score of -0.33 indicating that Biophytis is being referred to more favorably in the news media.

Company	Overall Sentiment
Can-Fite BioPharma	Neutral
Biophytis	Neutral

Summary

Can-Fite BioPharma beats Biophytis on 7 of the 10 factors compared between the two stocks.

Get Biophytis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPTSY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BPTSY vs. The Competition

Export

Metric	Biophytis	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$586K	$12.35B	$7.12B	$12.83B
Dividend Yield	N/A	2.62%	2.56%	10.57%
P/E Ratio	N/A	797.19	272.98	25.18
Price / Sales	N/A	756.79	620.42	83.61
Price / Cash	N/A	90.55	77.33	51.83
Price / Book	-0.02	10.39	10.33	6.20
Net Income	-$18.43M	$2.82B	$3.49B	$358.38M
7 Day Performance	N/A	-3.45%	-3.25%	-2.35%
1 Month Performance	N/A	1.35%	-0.23%	-2.60%
1 Year Performance	N/A	2.81%	17.33%	8.08%

Biophytis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BPTSY Biophytis	N/A	$0.25 flat	N/A	N/A	$586K	N/A	N/A	30
ORGS Orgenesis	N/A	$0.45 +9.1%	N/A	+250.0%	$2.33M	$662K	N/A	150	Gap Down
ATXI Avenue Therapeutics	N/A	$0.65 +20.7%	N/A	-4.2%	$2.15M	N/A	0.04	4
JAGX Jaguar Animal Health	0.2622 of 5 stars	$0.36 -12.6%	N/A	-99.6%	$1.87M	$11.51M	N/A	50	Short Interest Increase Gap Up High Trading Volume
ITRM Iterum Therapeutics	0.0223 of 5 stars	$0.03 flat	N/A	N/A	$1.60M	$390K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BPTSY) was last updated on 9/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biophytis (BPTSY) Competitors

BPTSY vs. ORGS, ATXI, JAGX, ITRM, and CANF

How does Biophytis compare to Orgenesis?

Summary

How does Biophytis compare to Avenue Therapeutics?

Summary

How does Biophytis compare to Jaguar Animal Health?

Summary

How does Biophytis compare to Iterum Therapeutics?

Summary

How does Biophytis compare to Can-Fite BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTSY vs. The Competition

Biophytis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biophytis (BPTSY) Competitors

BPTSY vs. ORGS, ATXI, JAGX, ITRM, and CANF

How does Biophytis compare to Orgenesis?

Is ORGS or BPTSY more profitable?

Do institutionals and insiders hold more shares of ORGS or BPTSY?

Which has more volatility & risk, ORGS or BPTSY?

Which has preferable valuation and earnings, ORGS or BPTSY?

Does the media prefer ORGS or BPTSY?

Summary

How does Biophytis compare to Avenue Therapeutics?

Which has more volatility & risk, BPTSY or ATXI?

Is BPTSY or ATXI more profitable?

Do institutionals and insiders believe in BPTSY or ATXI?

Which has better earnings and valuation, BPTSY or ATXI?

Does the media refer more to BPTSY or ATXI?

Summary

How does Biophytis compare to Jaguar Animal Health?

Does the media prefer BPTSY or JAGX?

Do institutionals and insiders hold more shares of BPTSY or JAGX?

Which has better earnings & valuation, BPTSY or JAGX?

Which has more risk and volatility, BPTSY or JAGX?

Do analysts rate BPTSY or JAGX?

Is BPTSY or JAGX more profitable?

Summary

How does Biophytis compare to Iterum Therapeutics?

Which has more risk & volatility, ITRM or BPTSY?

Is ITRM or BPTSY more profitable?

Does the media favor ITRM or BPTSY?

Which has better earnings and valuation, ITRM or BPTSY?

Do insiders and institutionals have more ownership in ITRM or BPTSY?

Do analysts prefer ITRM or BPTSY?

Summary

How does Biophytis compare to Can-Fite BioPharma?

Which has better valuation & earnings, CANF or BPTSY?

Do analysts rate CANF or BPTSY?

Do institutionals and insiders hold more shares of CANF or BPTSY?

Which has more risk and volatility, CANF or BPTSY?

Is CANF or BPTSY more profitable?

Does the media prefer CANF or BPTSY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTSY vs. The Competition

Biophytis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools